Your browser doesn't support javascript.
loading
Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir.
Jiang, Xiangrui; Su, Haixia; Shang, Weijuan; Zhou, Feng; Zhang, Yan; Zhao, Wenfeng; Zhang, Qiumeng; Xie, Hang; Jiang, Lei; Nie, Tianqing; Yang, Feipu; Xiong, Muya; Huang, Xiaoxing; Li, Minjun; Chen, Ping; Peng, Shaoping; Xiao, Gengfu; Jiang, Hualiang; Tang, Renhong; Zhang, Leike; Shen, Jingshan; Xu, Yechun.
Afiliação
  • Jiang X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Su H; University of Chinese Academy of Sciences, 100049, Beijing, China.
  • Shang W; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Zhou F; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.
  • Zhang Y; State Key Laboratory of Neurology and Oncology Drug Development, 210023, Nanjing, China.
  • Zhao W; Simcere Zaiming Pharmaceutical Co., Ltd, 200000, Shanghai, China.
  • Zhang Q; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Xie H; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Jiang L; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Nie T; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Yang F; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 210023, Nanjing, China.
  • Xiong M; Simcere Zaiming Pharmaceutical Co., Ltd, 200000, Shanghai, China.
  • Huang X; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Li M; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 210023, Nanjing, China.
  • Chen P; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Peng S; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203, Shanghai, China.
  • Xiao G; University of Chinese Academy of Sciences, 100049, Beijing, China.
  • Jiang H; Simcere Zaiming Pharmaceutical Co., Ltd, 200000, Shanghai, China.
  • Tang R; Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, 201210, Shanghai, China.
  • Zhang L; Jiangsu Simcere Pharmaceutical Co., Ltd, 210023, Nanjing, China.
  • Shen J; State Key Laboratory of Neurology and Oncology Drug Development, 210023, Nanjing, China.
  • Xu Y; Jiangsu Simcere Pharmaceutical Co., Ltd, 210023, Nanjing, China.
Nat Commun ; 14(1): 6463, 2023 10 13.
Article em En | MEDLINE | ID: mdl-37833261
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Animals / Female / Humans / Male Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China